Replies to post #37629 on Ethema Health Corp (GRST)

[Bubae]

I certainly don't need to point out that there are many others that have better stories than this one that most certainly didn't drop 510 million shares Q3 alone and over a billion so far this year. Your watch list is probably full of better plays. This same story keeps getting told over and over again for years and it gets worse.

Starting in November the LABRYS fund alone will need to convert around 800 million shares in the following 6 months to pay off the $780K in financing. I am expecting the company to refinance again to kick some that debt down the road and to raise more operating funds. They appear to do this every 6 months so they are due. I also doubt the $230K in the June financing will allow them to operate much longer without a refresh. They also need another "paid off debt" PR which traders here love to chase.

So the good news is that the promotions and permanent posts here work. This allows those of us to flip while most of the float holds and stays hopeful that they will recover their funds. This is a flip story stock until the reverse split is announced in my opinion and always has been in my opinion.


https://sec.report/Document/0001721868-21-000524/

"On May 7, 2021, the Company, entered into a Securities Purchase Agreement with Labrys, pursuant to which the Company issued a Convertible Promissory Note in the aggregate principal amount of $550,000 for net proceeds of $477,700 after an original issue discount of $55,000 and certain legal expenses of $17,300. The Note has a maturity date of May 7, 2022 and bears interest at the rate of eleven percent per annum from the date on which the Note was issued until the same became due and payable, whether at maturity or upon acceleration or by prepayment or otherwise. The Company has the right to prepay the Note in terms of agreement. The outstanding principal amount of the Note was convertible at any time and from time to time at the election of Labrys during the period beginning on the date that is 180 days following the issue date into shares of the Company’s common stock at a conversion price equal to $0.005, subject to anti-dilution adjustments."

"On June 2, 2021, the Company, entered into a Securities Purchase Agreement with Labrys, pursuant to which the Company issued a Convertible Promissory Note in the aggregate principal amount of $230,000 for net proceeds of $200,000 after an original issue discount of $23,000 and certain legal expenses of $7,000. The Note has a maturity date of June 2, 2022 and bears interest at the rate of eleven percent per annum from the date on which the Note was issued until the same became due and payable, whether at maturity or upon acceleration or by prepayment or otherwise. The Company has the right to prepay the Note in terms of agreement. The outstanding principal amount of the Note was convertible at any time and from time to time at the election of Labrys during the period beginning on the date that is 180 days following the issue date into shares of the Company’s common stock at a conversion price equal to $0.004, subject to anti-dilution adjustments."


https://sec.report/Document/0001721868-21-000350/

anti-dilution adjustment based on par value for conversion is .01

1.1 Conversion Right. The holder on any calendar day, at any time on or following the issue date, to convert all or any portion of the then outstanding and unpaid Principle Amount and interest (including any Default Interest) into fully paid and non-assessable shares of Common Stock.

1.2 Conversion Price

(a) Calculation of Conversion Price The per share conversion price into which Principle Amount and interest (including any Default Interest) under this Note shall be convertible into Common Stock hereunder (the “Conversion Price”) shall equal $0.005. If at any time the Conversion Price as determined hereunder for any conversion would be less than par value of the common stock, then at the sole discretion of the Holder, the conversion price hereunder may equal such par value for such conversion and the Conversion Amount for such conversion may be increased to include Additional Principle, where “Additional Principle” means such additional amount to be added to the conversion amount to the extent necessary to cause the number of conversion shares issuable upon such conversion to equal the same number of conversion shares as would have been issued had the Conversion Price not been adjusted by the Holder to the par value price.

[cybermich]

I would save your breath:)

this stock ran from .0001 to a penny and a half (I will let others figure out what kind of percentage gain that is.. hint: it is thousands and thousands of percent)..

even at today's price.. we are up thousands of percent from the basement.

But how is this acknowledged?.. it is portrayed as "an old story".. or just "a trading opportunity"

well guess what?.. call it anything you want:).. people "trade" on the OTC.. because of runs like that..

where else are you going to get Thousands of percent gains in that period of time?.. (well, maybe crypto.. lol)

bottom line.. there is NO denying the fact that GRST ran all those thousands of percent.. AND the "story" was not as advanced as it is today (translation: we are in imo a BETTER spot as a company as we were a year ago).. but some will even debate that point:).. so be it.

with all the "flaws" this company has.. call it a trading opportunity, a short term opportunity or label it as something else..

as an OTC company.. imo there is a chance/opportunity to make good gains here.

xqsme_imnew, by your post I think you probably get what I am saying:)..
it's relative when you look at the rest of the OTC landscape:).. nobody said that GRST is perfect, but those who have experience on the OTC can recognize an opportunity when they see one.

AIMHO of course..

Cy